Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Levofloxacin + azithromycin is a fixed-dose combination of two antibiotics used to treat a variety of bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and cervicitis. Levofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and repair in bacteria. Azithromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the nascent peptide exit tunnel on 23S rRNA. The combination provides broad-spectrum coverage against both gram-positive and gram-negative bacteria as well as atypical pathogens. Clinical studies suggest this combination may be more effective than monotherapy in certain indications such as cervicitis[1][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levofloxacin + azithromycin.